

It is made available under a CC-BY-NC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.03.23295000;](https://doi.org/10.1101/2023.09.03.23295000) this version posted September 4, 2023. The copyright holder for this preprint

Abstract

Introduction: Atrial septal aneurysms increase the risk of stroke recurrence in cryptogenic stroke patients with a patent foramen ovale. Factors related to stroke recurrence according to the patent foramen ovale risk stratification have not been fully evaluated. **Methods:** Data from a multicenter observational registry of ischemic stroke patients undergoing transesophageal echocardiography, with a comprehensive database including clinical characteristics and long-term prognosis, were used for this study. Patients were classified into three groups: high-risk patent foramen ovale group, large shunt patent foramen ovale (≥20 microbubbles) or patent foramen ovale with atrial septal aneurysm; right-to-left shunt group, right-to-left shunt including patent foramen ovale with <20 microbubbles or without atrial septal aneurysm; and negative right-to-left shunt group. Among stroke subtype, factors related to stroke recurrence were investigated according to the risk stratification of patent foramen ovale in cryptogenic stroke. **Results:** In total, 586 patients (185 females; 65.5 ± 13.2 years) were analyzed. In cryptogenic stroke (329 patients) with median follow-up of 4.2 (interquartile range, 1.0– 6.1) years, 55 patients had stroke recurrence. The negative right-to-left shunt, right-to-left shunt, and high-risk patent foramen ovale groups included 179, 90, and 60 patients, in which stroke recurrence occurred in 5.3%, 2.5%, and 4.6% per person-year, respectively. In patients with high-risk patent foramen ovale, the NIH stroke scale score (hazard ratio 1.257, 95% CI 1.034-1.530, *P*=0.022) and periventricular hyperintensity (hazard ratio 3.369, 95% CI 1.103-10.294, *P*=0.035) were predictive markers for stroke

Introduction

Methods

Study population

pressure >90 mmHg after the 14th admission day or use of antihypertensive drugs.

20 Diabetes mellitus was defined as hemoglobin A1c levels $\geq 6.5\%$ on admission or the use

- 21 of antidiabetic drugs. Dyslipidemia was defined as low-density lipoprotein cholesterol \ge
- 22 140 mg/dl, high-density lipoprotein cholesterol < 40 mg/dl, triglycerides ≥ 150 mg/dl,
- or the use of lipid-lowering drugs. Ischemic heart disease included myocardial

1 infarction, angina pectoris, and coronary artery stenosis. Chronic kidney disease was

2 defined as an estimated glomerular filtration rate (eGFR) ≤ 60 ml/min/1.73 m².

3 **MRI sequences**

- 4 MRI was performed at each institution with 1.5- or 3-T scanners during
- 5 hospitalization. Sequences included axial diffusion-weighted imaging (DWI), fluid-
- 6 attenuated inversion recovery imaging (FLAIR), magnetic resonance angiography
- 7 (MRA), and the GRE T2* sequence. DWI (repetition time (TR) / echo time (TE)
- $8 = 4156-7000/60-120$ ms) was used to assess the size and distribution of the index stroke
- 9 lesions. FLAIR (TR/TE = 6879-10000/105-120 ms) was used to evaluate the degree of
- 10 deep and subcortical white matter hyperintensity (DSWMH) and periventricular
- 11 hyperintensity (PVH) in accordance with Fazekas grades $0-3$.¹¹ MRA (TR/TE = 19-
- 12 30/2.8-6.9 ms) was used to detect intracranial stenosis >50% not relevant to the
- 13 infarction area. Examinations were performed by two or three experienced sonographers
- 14 in each institution.

15 **TEE study**

16 TEE was performed as explained in our previous work.¹² An ASA was defined as a 17 \geq 10-mm excursion into either the left or right atrium, or a sum of total excursion into 18 the left or right atrium of \geq 15 mm. The right-to-left shunt (RLS) was assessed by 19 injecting agitated saline and having patients perform the Valsalva maneuver. 20 Subsequently, the number of microbubbles with and without contrast agents was 21 compared, and the number transiting from the right to the left atrium was counted. PFO 22 was diagnosed when microbubbles were visualized in the left atrium \leq 2 cardiac cycles 23 after the Valsalva maneuver, whereas a pulmonary arteriovenous fistula was diagnosed 24 when microbubbles were visualized in the left atrium >3 cardiac cycles after the

Valsalva maneuver or when microbubbles were visualized without the Valsalva

maneuver.

Classification of patients based on the presence of RLS

Based on the presence or absence of RLS, patients were classified into three groups:

negative RLS group, lacking RLS; RLS group, RLS including a PFO or pulmonary

arteriovenous fistula with a small-to-moderate shunt (<20 microbubbles) or without

7 ASA; and high-risk PFO group, having a large-shunt PFO $(\geq 20$ microbubbles) or

concurrent ASA.

Data collection for analyses and outcome measures

Baseline clinical information and radiological and echocardiographic data during

hospitalization were collected through hospital charts or database reviews. During the

study period from May 2021 to December 2021, such data were retrospectively

obtained. The primary outcome of stroke recurrence, for any type of stroke occurrence

such as brain infarction, transient ischemic attack, intracranial hemorrhage, and

subarachnoid hemorrhage, was also extracted from hospital charts or database reviews.

In enrolled patients, ischemic stroke subtype was determined according to the Trial of

17 Org 10172 in Acute Stroke Treatment (TOAST) criteria.¹³ Clinical characteristics were

compared between cryptogenic stroke and other stroke subtype, and factors related to

stroke recurrence were investigated in the negative RLS, RLS, and high-risk PFO

- groups, in cryptogenic stroke.
- **Statistical analysis**

22 Data are presented as number $(\%)$, mean \pm standard deviation, and median (interquartile range) values. Patients' characteristics and baseline data were compared

between the two groups. Continuous variables were compared using the Mann-Whitney

It is made available under a CC-BY-NC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.03.23295000;](https://doi.org/10.1101/2023.09.03.23295000) this version posted September 4, 2023. The copyright holder for this preprint

2 3], *P*=0.053) was relatively higher than in patients without stroke recurrence. Degrees of PVH and DSWMH were significantly higher in patients with stroke recurrence than in patients without stroke recurrence (1.7±1.0 vs. 0.8±1.0, *P*=0.003; 1.3±1.0 vs. 0.7±0.8, $P=0.041$).

Factors associated with stroke recurrence according to the presence of RLS

8 The incidence of stroke recurrence in the three groups was 5.3%, 2.5%, and 4.6% per

person-year, respectively. In the negative RLS group, dyslipidemia, previous history of

ischemic stroke, multiple infarctions, and large infarct > 3.0 cm reached *P*<0.2 on

univariate Cox hazards analysis and were entered into the multivariate Cox hazards

analysis. However, no factors were found to predict stroke recurrence (Table 3). In the

RLS group, the univariate Cox hazards analysis showed that PVH and DSWMH

significantly predicted stroke recurrence (hazard ratio [HR] 2.319, 95% CI 1.257-4.277,

P=0.007; HR 2.506, 95% CI 1.349-4.654, *P*=0.004). However, multivariate analysis

found no factors predicting stroke recurrence (Table 4). In the high-risk PFO group,

NIHSS score on admission (HR 1.346, 95% CI 1.147-1.579, *P*<0.001), PVH (HR 2.520,

95% CI 1.417-4.484, *P*=0.002), and DSWMH (HR 2.547, 95% CI 1.296-5.008,

P=0.007) showed significant differences and were entered into the multivariate Cox

hazards model. The NIHSS score on admission (HR 1.257, 95% CI 1.034-1.530,

P=0.022) and PVH (HR 3.369, 95% CI 1.103-10.294, *P*=0.035) were found to be

predictive markers for stroke recurrence (Table 5). The Kaplan-Meier survival curves

showed that cumulative event-free rates were significantly lower in patients with a

present registry study showed that cryptogenic stroke patients with high-risk PFOs had a 1.8 times higher stroke recurrence rate than cryptogenic stroke patients with RLS, but lower than that in the negative RLS group. Compared to the study by Mas et al., the patients enrolled in the present study were older and frequently had atherosclerotic vascular risk factors, leading to the presence of other embologenic diseases such as aortic complicated plaques and non-stenotic carotid plaques, which could be a cause of the higher rate of stroke recurrence in the negative RLS group. More importantly, high-risk PFO could be a risk factor for stroke recurrence in cryptogenic stroke over the entire age spectrum, particularly when comparing with RLS other than with high-risk PFO. PVH and DSWMH have been shown as degrees of cerebral white matter lesions.¹¹

Aging and hypertension are fundamental risk factors for the development of white 13 matter diseases.¹¹ Conversely, we previously reported the association of PVH with PFO, and in particular, the co-existence of PFO and ASA was associated with a higher degree 15 of white matter lesions than lone PFO, lone ASA, and neither of them.¹⁵ Several studies showed that PFO contributed to the development of white matter lesions in Alzheimer's 17 disease and decompression disease.^{16, 17} Conversely, no such relationship was found in patients with migraine and cerebral autosomal dominant arteriopathy with subcortical 19 infarcts and leukoencephalopathy.^{18, 19} In addition, cerebral perforating arteries can be 20 occluded by small emboli, 2^0 even paradoxical emboli.²¹ Thus, small emboli derived from a septal abnormality or the venous system might be related to recurrent stroke and 22 the development of white matter lesions.

Regarding treatment, patients who developed stroke by 2017, when percutaneous PFO closure was not approved in Japan, were enrolled. The frequency of antiplatelet

- None
- **Funding**

- This work was funded, in part, by the BMS/Pfizer Japan Thrombosis Investigator
- Initiated Research Program (JRISTA).

Potential Conflicts of Interest

None declared.

Data availability statement

The datasets used and analyzed during the current study are available from the

Reference

Table 1. Baseline characteristics, MRI findings, and laboratory data of the cryptogenic stroke and other stroke subtype groups

Chi-square test, and the Mann-Whitney test were used for comparison. MRI = Magnetic Resonance Imaging, SD = standard deviation, NIHSS = National Institute of Health Stroke Scale, $IQR =$ interquartile range, $PVH =$ periventricular hyperintensity, $LDL-C =$ low-density lipoprotein cholesterol. Missing value: a) = 17 , b) = 4, c) = 18, d) = 16.

Table 2. Baseline characteristics, MRI findings, and laboratory data according to the presence of stroke recurrence in cryptogenic stoke with negative RLS, RLS, and high-risk PFO

Chi-square test, and the Mann-Whitney test were used for comparison. MRI = Magnetic Resonance Imaging, RLS = light to left shunt, PFO = patent foramen ovale, SD = standard deviation, NIHSS = National Institute of Health Stroke Scale, \overline{IQR} = interquartile range, PVH = periventricular hyperintensity, LDL-C = low-density lipoprotein

cholesterol. Missing value: a) = 13, b) = 4, c) = 14, d) = 11.

MRI = Magnetic Resonance Imaging, RLS = light to left shunt, HR = hazard ratio, CI = confidence interval NIHSS = National Institute of Health Stroke Scale, PVH = periventricular hyperintensity, LDL-C = low-density lipoprotein cholesterol. Missing value: a) = 13, b) = 4, c) = 14, d) = 11.

Table 4. Univariate and multivariate analyses of baseline characteristics, MRI findings, and laboratory data predicting stroke recurrence in cryptogenic stroke with RLS

 $MRI =$ Magnetic Resonance Imaging, $RLS =$ light to left shunt, $HR =$ hazard ratio, $CI =$ confidence interval NIHSS = National Institute of Health Stroke Scale, PVH = periventricular hyperintensity, LDL-C = low-density lipoprotein cholesterol. Missing value: a) = 13, b) = 4, c) = 14, d) = 11.

Table 5. Univariate and multivariate analyses of baseline characteristics, MRI findings, and laboratory data predicting stroke recurrence in cryptogenic stroke with high-risk PFO

MRI = Magnetic Resonance Imaging, PFO = patent foramen ovale, HR = hazard ratio, CI = confidence interval NIHSS = National Institute of Health Stroke Scale, PVH = periventricular hyperintensity, DSWMH = deep and subcortical hite matter hyperintensity, LDL-C = low-density lipoprotein cholesterol. Missing value: a) = 13, b) = 4, c) = 14, d) = 11.

Figure legends

Figure 1. COCTAIL-TEE = Clinical Observation, Characteristics, and prognosis for long-term of stroke patients undergoing TransEsophageal Echocardiography, RLS = right-to-left shunt, PFO = patent foramen ovale.

Figure 2. Kaplan-Meier curves of freedom from stroke recurrence during follow-up. The X axis indicates time in days since inclusion in the study. The Y axis indicates the proportion of patients surviving free of stroke recurrence. Cumulative event-free rates are compared among degrees of periventricular hyperintensity in the negative RLS (**A**), RLS (**B**), and high-risk PFO (**C**) groups. RLS = right-to-left shunt, PFO = patent foramen ovale.

Figure 3. Proportion of antiplatelet and anticoagulant therapies for secondary prevention in the negative RLS, RLS, and high-risk PFO groups.

 $ACT = anticoagulant$ therapy, $APT = antiplated$ therapy, $RLS = right$ -to-left shunt, $PFO = patent$ foramen ovale.

It is made available under a CC-BY-NC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.03.23295000;](https://doi.org/10.1101/2023.09.03.23295000) this version posted September 4, 2023. The copyright holder for this preprint

